Please Wait...

Time to Take Action and Make Risk-Based Monitoring a Reality

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

The current state of RBM and how to implement a successful program are explored in a recent article I authored for the December 2014 edition of EPC (European Pharmaceutical Contractor), entitled Risk-Based Monitoring: A Little More Action. We begin with a look at the EMA definition of quality risk-based management and how it sets the foundation for successful RBM, grounding us in why we're doing RBM in the first place.

European Pharmaceutical ContractorWe also examine the Quality by Design (QbD) process as it provides a clear understanding of your study risks. It's this QbD process that sets you on course to take action and mitigate risks through monitoring. It also enables you to adapt your plans moving forward.

Intelligent risk-based monitoring employs a robust quality process backed by technology to help make sense of the thousands, if not millions, of data points in a trial. To ensure you have the right tools to implement your RBM method, there are some important considerations when evaluating technologies. These include integration ability, data types and sources, KPIs and other factors, all of which are discussed in the article.

One of the major stumbling blocks to RBM I'm seeing with organizations both in the US and Europe is an exhaustive search to find the best monitoring method (when in fact there is no single best method!). While factors like these pose barriers to implementation, the good news many resources are available to help you overcome them so there's no time like the present to get started!

 

Preview Compass Technology

If you'd like to preview BioClinica's RBM-enabling Compass technology, an on-demand webinar is available to watch at your convenience. In it we explore the Intelligent Monitoring approach aimed at raising overall clinical trial quality while reducing risk. I encourage you to watch it if you're having trouble moving your program forward.

In the meanwhile, if you'd like to talk about RBM or need an answer to a specific question, shoot me an email at Courtney.McBean[a]BioClinica.com and I'll walk you through it. I'd love to hear from you about what is, or is not, working for you in your own clinical trials.

Overcoming Barriers to Risk Based Monitoring

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

ICYMI: Clean Patient Optics: helping #ClinicalResearch teams meet or beat database lock. News https://t.co/pUem5e2cMG
bioclinica (25 minutes ago)
Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (2 days ago)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (3 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (5 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (5 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (5 days ago)

Latest Blogs: